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Abstract Acute tryptophan depletion (ATD) is a method
of reducing central nervous serotonin (5-HT) synthesis in
humans by administering an amino acid (AA) beverage
lacking in tryptophan (TRP), the physiological precursor of
5-HT. However, to date, the use of conventional ATD
protocols in children and adolescents was limited due to
frequently observed side effects (e.g., vomiting and nau-
sea). This study investigated the effects of diminished
central nervous system 5-HT synthesis on plasma con-
centrations of relevant AAs and TRP influx into the brain
in 24 healthy young adults using the ATD procedure Moja-
De, a test protocol that has been used in preliminary
research in youths. Twenty-four healthy participants
received ATD and a TRP-balanced amino acid load (BAL)
using a randomized double-blind within-subject crossover
design. Plasma concentrations of the relevant AAs that
compete with TRP on the same transport system were
assessed at baseline and 90, 180, and 240 min after ATD/
BAL intake. TRP influx across the blood–brain barrier was
calculated using Michaelis–Menten kinetics with a cor-
rection for multiple substrate competition, indicating a
significant decrease in TRP influx into the central nervous
system under Moja-De. ATD Moja-De decreased TRP
influx into the brain and central nervous system 5-HT
synthesis safely and effectively and was well tolerated,
allowing it to be used in children and adolescents. Future
research into other secondary, compensatory effects
induced by ATD in patients with neuropsychiatric disor-
ders and healthy populations is needed. ATD Moja-De
allows this type of research with a focus on a develop-
mental viewpoint.
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Introduction
The neurotransmitter serotonin (5-HT) plays an important
role in many neuropsychiatric disorders and behavioral
phenotypes, in particular, affective disorders, eating and
attention disorders along with their changed cognitive
processes, aggressive behavior and impulsivity. To date,
several methods have been used to probe the effects of
central nervous 5-HT in the described patient populations
and in healthy subjects. Along with the study of genetic
differences between healthy controls and patients with
various neuropsychiatric disorders, several strategies have
been adopted to study 5-HT function, such as the assess-
ment of the 5-HT metabolite 5-HIAA in cerebrospinal
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fluid, the prolactin (PRL) response to fenfluramine (FEN)
administration, and the uptake of 5-HT in platelets. How-
ever, studying central nervous 5-HT function in children
and adolescents is difficult, particularly because many
previously used methods are rather invasive (i.e., such as
the assessment of 5-HIAA in CSF) or cannot be undertaken
because of cardiac risks, especially valvular heart disease
[PRL–FEN response, (Connolly et al. 1997; Graham and
Green 1997; Li et al. 1999)]. In addition, the administration
of SSRIs to youths as a way to probe central nervous 5-HT
function by enhancing the availability of 5-HT is limited in
terms of randomized controlled trials, in particular when
healthy controls are involved.
Acute tryptophan depletion (ATD) is one possible way
to achieve a short-term serotonergic dysfunction in the
central nervous system in humans. The administration of an
amino acid beverage that lacks TRP, the physiological
amino acid precursor of 5-HT, diminishes its uptake into
the brain. ATD occurs because all the relevant amino acids
in the beverage use the same active large neutral amino
acid (LNAA) transport system (L-1) in the capillary cell
plasma membrane to pass the blood–brain barrier. The
L-transport system was localized in different kinds of cells
in the human body. However, the L-1-system at the cap-
illary endothelial cells of the blood–brain barrier differs
from the L-system found in other human cells (as for
example in the gastrointestinal tractus, hepatic and renal
tissue) because of its 100- to 1,000-fold higher affinity for
the outlined amino acids (Oldendorf and Szabo 1976;
Kewitz 2002). In past research the sum for the unidirec-
tional influx of all LNAAs was calculated with 50 nmol/
min/g brain tissue (Oldendorf and Szabo 1976; Smith et al.
1987a, b). As was demonstrated by previous work, the
uptake of amino acids using L-1 at the blood–brain barrier
marks a facilitated diffusion of amino acids into the brain
and follows Michaelis–Menten kinetics with competitive
substrate inhibition (Smith et al. 1987a, b; see also Kewitz
2002). In order to determine influx-properties and affinity
constants of different amino acids in order to be able to
calculate influx rates several in vitro and in vivo methods
were developed (e.g., in vitro measurements with isolated
capillary endothelial cells of the blood–brain barrier,
indicator-dilution technique, etc., see Kewitz 2002 and
Pardridge 1998). Such information on affinity constants
and influx rates of different amino acids is of particular
importance in order to perform quantitative calculations in
humans. As outlined by Kewitz (2002), the affinity towards
L-1 of different amino acids is correlated with the polarity
of the molecules, and unipolar hydrophobic amino acids
(such as tryptophan and phenylalaline) were shown to have
the highest affinity with respect to L-1 as indexed by their
rather low Km values (in enzyme kinetics, Km values
approximate the affinity of a particular enzyme for a
specific substrate). For example, a low Km value is indic-
ative of a rather high affinity of a particular amino acid for
the L-1 transporter, which in turn leads to a faster
accomplishment of the maximum rate of conversion
(Vmax). In contrast to this, a high Km value would lead to a
slower accomplishment of Vmax. As was shown by animal
research the uptake of LNAAs into the brain is saturated
under physiological conditions, and this process is con-
sidered to be independent of sodium (Pardridge 1998;
Smith 2000). The underlying concept of ATD, a physio-
logical neurodietary method to lower central nervous 5-HT
synthesis in humans, builds on the increase in plasma
concentrations of other amino acids as achieved by their
dietary administration (often after an overnight fasting
period), which in turn impacts the transcapillary influx of
TRP over the blood–brain barrier which follows the
underlying principles of facilitated diffusion. The admin-
istration of an amino acid beverage without TRP causes the
competitive antagonism at the L-1 of the consumed com-
peting amino acids (CAAs) with endogenous TRP. Due to
these amino acids, the overall influx of TRP across the
blood–brain barrier is diminished. As a result of the
decreased TRP uptake into the central nervous system
(CNS), there is reduced substrate availability for trypto-
phan hydroxylase 2 (TPH2, which is half-saturated under
physiological conditions), the enzyme that limits the rate of
synthesis of 5-HT in the CNS. Moreover, amino acid intake
stimulates protein synthesis in the liver. This synthesis
requires additional TRP from plasma stores and contributes
to 5-HT depletion, in addition to the passive diffusion of
amino acids across the blood–brain barrier (Zepf 2012).
We recently developed a new ATD protocol, Moja-De,
that administers relevant amino acids depending on body
weight (Kewitz 2002; Demisch et al. 2002), allowing its
use in children and adolescents without the side effects,
such as vomiting and nausea, that were frequently observed
in adult populations (Zepf et al. 2008b, 2009c). This
weight-adapted protocol takes a positive correlation
between body weight and plasma TRP into account
(Kewitz 2002; Demisch et al. 2002). This particular pro-
tocol is well tolerated and can be used in children and
adolescents (Stadler et al. 2007; Zepf et al. 2008a, b, c,
2009d); however, to date, no publications have demon-
strated a decreased influx of TRP into the brain after Moja-
De administration. The present explorative approach
administered the ATD Moja-De procedure to healthy
young adults to validate the procedure used in this study
regarding its impact on TRP influx into the brain and its
influence on CNS 5-HT synthesis. We calculated the influx
data for TRP entering the brain across the blood–brain
barrier under the influence of the ATD Moja-De paradigm
versus a balanced amino acid load (BAL) that served as the
control condition.
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Methods
Study design
This study employed a randomized double-blind within-
subject repeated-measures design to administer ATD and
BAL on different days. The ATD/BAL administration was
a within-subject repeated-measures factor. After an over-
night protein fast, the participants received the ATD/BAL
amino acids in a beverage each morning. Before ATD/BAL
intake, a baseline (T0) blood sample, drug screen, and
pregnancy tests (in females) were administered. Three
additional blood samples were taken 90 min (T1), 180 min
(T2), and 270 min (T3) after the ATD/BAL intake each
day.
Sample
The sample consisted of 24 participants aged 21–30 years
(12 males and 12 females; mean age = 25.34 ± 2.09 -
years). The mean weight of the whole sample was
70.54 ± 11.86 kg, the mean BMI was 23.04 ± 1.86 kg/m2.
The complete demographic data of the study sample with
respect to the two genders are provided as Supplementary
Online Material. The Ethics Committee of the Faculty of
Medicine, RWTH Aachen University, approved the study
protocol. The inclusion criteria were good physical and
mental health, as assessed by an experienced clinician
through an interview. The exclusion criteria were an IQ
under 85, the presence of a developmental disorder,
schizophrenia, affective disorder, psycho-organic syn-
drome, drug abuse, somatic disease, the regular use of
medication, and pregnancy. Before the study, the partici-
pants were screened for psychiatric disorders using a
standardized interview [SKIDPIT-light; (Demal 1999)]. All
the participants provided oral and written informed consent
to participate in the study. The participants were financially
compensated after the study.
Depletion procedure
Prior to study participation, recommendations for a stan-
dard breakfast containing no TRP were provided to all
participants. All participants confirmed that they had fol-
lowed these recommendations on each day of testing.
Moja-De administers amino acids (AAs) within an aqueous
suspension, in which the relevant AA quantities are in
accordance with the participants’ body weights (Stadler
et al. 2007; Zepf et al. 2008a, b, c, 2009a, b, d; Zepf and
Poustka 2008). After an overnight protein fast, some par-
ticipants received ATD on 1 day and BAL on another day;
other participants received these solutions in the reverse
order. The AA quantities in Moja-De were as follows
(dosage per 10 kg of body weight): L-phenylalanine (PHE
1.32 g), L-leucine (LEU 1.32 g), L-isoleucine (ILE 0.84 g),
L-methionine (MET 0.5 g), L-valine (VAL 0.96 g), L-thre-
onine (THR 0.6 g), and L-lysine (LYS 0.96 g). The BAL
beverage contained the same AA quantities with an addi-
tional 0.7 g of TRP per 10 kg of body weight. Nine par-
ticipants (37.5 %, six females and three males) received
ATD on their first day, and 15 participants (62.5 %, six
females and nine males) received ATD on their second day
of participation.
Laboratory assessment
Blood samples were collected for each time point in hep-
arinized and nonheparinized tubes. After collection, they
were kept at room temperature for 30 min and then cen-
trifuged at 3,500g for 10 min. Subsequently, the remaining
serum and plasma were placed in new tubes, and all the
tubes were kept at -80 C until their transportation to the
laboratory and analysis. Plasma AA concentrations were
assessed using high-pressure liquid chromatography
(HPLC) after precolumn derivatization using ortho-
phthaldialdehyde (OPA). Albumin-bound TRP was sepa-
rated from free TRP using an Amicon Ultra-0.5 centrifugal
filter at 14,000g for 30 min (Merck-Millipore, Darmstadt,
Germany), which retains compounds larger than 10 kDa.
Calculation of the TRP influx into the brain
TRP influx across the blood–brain barrier into the brain is
characterized by unidirectional uptake and depends on TRP
concentrations and competing LNAAs. The brain capillary
LNAA carrier L-1 is the main transport mechanism for
LNAAs, and these cannot be synthesized in the CNS
(Oldendorf and Szabo 1976; Pardridge 1983; Smith and
Stoll 1998). As a consequence, the unidirectional influx
rates for the AA uptake from the plasma into the brain in
terms of a transcapillary influx following facilitated diffu-
sion at L-1 can be calculated using the Michaelis–Menten
equation with a correction for multiple substrate competi-
tion (Pardridge 1983; Smith et al. 1987a). As regards the
used approach Michaelis–Menten kinetics provide a simple
and valid mathematical model to describe the relationship
between a substrate and its availability after reaction of the
substrate with an enzyme to form a specific product.
Briefly, Michaelis–Menten kinetics can describe the con-
version of a substrate by an enzymatic mechanism with
respect to the availability and concentration of the sub-
strate, and provide an approximation for the reaction rate.
The net uptake of TRP over the blood–brain barrier in
terms of a transcapillary influx at L-1 builds on two major
components: the outlined passive transport of amino acids
at L-1 that can be facilitated by integral proteins, and a
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further proportion that follows passive diffusion (Kewitz
2002). The formula based on Michaelis–Menten kinetics
that was used to calculate the influx-rate of tryptophan over
the blood–brain barrier (see Kewitz 2002) was
TRP influx ¼ VmaxC= Km 1 þ
X
ðCi=KiÞ
h i
þ C
 
þ KdC
with C = plasma concentration of TRP, Vmax = maximum
rate of conversion, Km = affinity constant for TRP
(Michaelis constant), Ci = plasma concentration of CAAs,
Ki = affinity constants of CAAs, Kd = diffusion constant.
Of note, Km resembles the substrate concentration that is
related to the rate of conversion that resembles 50 % of
Vmax for the relevant amino acid. In order to perform the
above-mentioned calculations, transport constants for dif-
ferent amino acids from previously published studies were
adopted and implemented into the mathematical model
(Smith et al. 1987a, b; Smith and Stoll 1998).
Data analyses
The level of statistical significance was set at p \ 0.05.
Because of the exploratory nature of the present investi-
gation, significant p values were not subject to alpha
adjustments. All the dependent variables were tested for
normality using the Kolmogorov–Smirnov goodness of fit
test with regard to the full sample, and males and females
were also tested independently. Regarding the whole
sample, all the variables were normally distributed except
THR. Regarding the sexes separately, only the female VAL
levels were not normally distributed. Separate repeated-
measures analyses of variance (RMANOVAs) investigated
the following effects: ATD on TRP, ATD on fTRP plasma
concentrations, on the LNAA/TRP ratio, and on the influx
of TRP across the blood–brain barrier. Treatment (ATD vs.
BAL) and time after intake were the within-participant
factors, whereas sex was the between-participants factor.
The same within- and between-participant factors were
used for separate RMANOVAs to test the effect of ATD on
the other AA (i.e., ILEU, LEU, LYS, MET, PHE, THR,
TRP, fTRP, TYR, and VAL) concentrations.
Results
Effects of Moja-De on amino acid plasma
concentrations
Overall ATD Moja-De was well tolerated in the whole
sample. The different influx curves for TRP and fTRP are
given in Fig. 1a, b. Table 1 provides the degrees of free-
dom (df), F values (F), and significance (p value) of the
RMANOVAs for the different AAs. Treatment (ATD vs.
BAL, p \ 0.001–0.023) and (p \ 0.001–0.001) influenced
almost all the AA plasma levels significantly. Figure 2a, b
provides all the concentration means and standard devia-
tions of TRP and fTRP for the different treatment condi-
tions (ATD vs. BAL) and time points (T1–T3) in the whole
study sample. The data on the different AA concentrations
except TRP-derived parameters (TRP, fTRP) are provided
as Supplementary Online Material. Only TYR (which
was not included in the ATD and BAL beverages) was
unaffected by treatment [treatment F (1, 92) = 1.076,
p = 0.311; time F (2, 46) = 8.838, p = 0.001]. As expec-
ted, all the AA concentrations (except TRP) initially
increased after ATD administration (see Supplementary
Online Material). There were significant effects of both
treatment and time, as well as a significant treatment-by-
time interaction on the TRP and fTRP levels (see below;
Table 1), which indicates that there was a remarkable
decrease in TRP and fTRP plasma concentrations after ATD
intake for all post-administration time points (see Fig. 2a, b).
Effects of ATD and time on TRP concentrations, TRP
influx across the blood–brain barrier, and the TRP/CAA
ratio
Significant main effects of time after AA intake and
treatment and a significant treatment-by-time interaction of
TRP concentrations and TRP-related parameters were
detected (TRP/fTRP plasma levels, TRP/fTRP influx
across the blood–brain barrier, the TRP/CAA ratio, and the
fTRP/CAA ratio). After ATD ingestion, clear decreases in
total TRP and fTRP were observed, while after BAL
ingestion, both AAs increased [TRP treatment F (1, 92)
= 743.140, p \ 0.001; TRP time F (2, 46) = 19.034, p \
0.001; fTRP treatment F (1, 92) = 234.384, p \ 0.001;
fTRP time F (2, 46) = 35.198, p \ 0.001]. Similar
results were identified for the fTRP/CAA ratio [treatment
F (1, 92) = 187.409, p \ 0.001; time F (2, 46) = 4.514,
p = 0.016], the TRP/CAA ratio [treatment F (1, 92) =
764.177, p \ 0.001; time F (2, 46) = 9.652, p \ 0.001],
total TRP influx [treatment F (1, 92) = 1,340.715, p \
0.001; time F (2, 46) = 3.147, p = 0.053] and fTRP influx
[treatment F (1, 92) = 285.477, p \ 0.001; time F (2, 46)
= 4.464, p = 0.017]. These results show that these
parameters decreased after ATD intake but increased after
BAL intake, suggesting that ATD Moja-De lead to a robust
reduction in central nervous system TRP availability and
5-HT synthesis.
Discussion
ATD Moja-De ingestion significantly decreased plasma
TRP levels and consequently reduced TRP influx across the
V. L. S. Dingerkus et al.
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blood–brain barrier compared with BAL. This significant
reduction in the TRP influx into the brain occurred 90 min
after ATD intake and remained stable at this level 180 and
240 min later. Free and total TRP influxes significantly
decreased following ATD administration compared with
the baseline (85.324 for fTRP at T2 vs. T0 and 81.084 %
for TRP at T2 vs. T0, respectively). For ATD compared
with BAL, there was a maximum reduction in the TRP
Fig. 1 Influx curves (nmol/
min/g brain tissue) of the a total
and b free TRP across the
blood–brain barrier at the time
points T0–T3 after the intake of
acute tryptophan depletion
(ATD) and a balanced amino
acid load (BAL). The data are
represented as the mean
values ± SD
Table 1 Results including
degrees of freedom (df),
F values (F), and the
significance (p value) of
different repeated-measures
analyses of variance
(RMANOVAs) for the amino
acids isoleucine (ILE), leucine
(LEU), lysine (LYS),
methionine (MET),
phenylalanine (PHE), threonine
(THR), tryptophan (TRP), free
tryptophan (fTRP), and tyrosine
(TYR)
The within-participant factors in
the RMANOVA included ATD/
BAL treatment and time
(T1–T3); sex was a between-
participants factor
Amino acid Within-participant factors/interaction df F p value
ILE Treatment 1, 92 8.947 0.007
Time 2, 46 14.980 \0.001
Treatment 9 time 2, 92 3.114 0.054
LEU Treatment 1, 92 6.009 0.023
Time 2, 46 44.460 \0.001
Treatment 9 time 2, 92 1.954 0.154
LYS Treatment 1, 92 25.449 \0.001
Time 2, 46 150.016 \0.001
Treatment 9 time 2, 92 1.341 0.272
MET Treatment 1, 92 13.091 0.002
Time 2, 46 16.319 \0.001
Treatment 9 time 2, 92 1.463 0.243
PHE Treatment 1, 92 6.312 0.020
Time 2, 46 28.476 \0.001
Treatment 9 time 2, 92 1.549 0.224
THR Treatment 1, 92 32.633 \0.001
Time 2, 46 17.597 \0.001
Treatment 9 time 2, 92 0.831 0.443
TRP Treatment 1, 92 743.140 \0.001
Time 2, 46 19.034 \0.001
Treatment 9 time 2, 92 11.451 \0.001
fTRP Treatment 1, 92 234.384 \0.001
Time 2, 46 35.198 \0.001
Treatment 9 time 2, 92 31.166 \0.001
TYR Treatment 1, 92 1.076 0.311
Time 2, 46 8.838 0.001
Treatment 9 time 2, 92 0.745 0.481
VAL Treatment 1, 92 8.923 0.007
Time 2, 46 54.583 \0.001
Treatment 9 time 2, 92 1.626 0.208
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influx across the blood–brain barrier, as measured by
reduced fTRP levels at T3 (91.305 % under ATD vs. T0)
and total TRP levels at T2 (85.900 % under ATD vs. T0).
Overall, the data support the assumption that lowering
cerebral TRP availability using ATD Moja-De is a reliable
and tolerable method of studying CNS serotonin function.
This effect is likely due to Moja-De’s composition of dif-
ferent AA quantities and its weight-adapted test protocol.
ATD Moja-De promises to be a useful tool in additional
investigations of serotonin function in animal, adult, and
child studies. Our findings indicate that ATD Moja-De is
associated with lower plasma TRP concentrations (both
free and total TRP), which accords with the pilot work
conducted by Kewitz (Kewitz 2002; Demisch et al. 2002).
Because the present study used indirect methods to esti-
mate a decrease in central nervous TRP availability, the
Moja-De ATD protocol needs to be validated in animal
studies, which is the subject of ongoing research (Biskup
et al. 2012).
One major advantage of the present study is that it
provides evidence that ATD Moja-De decreases central
nervous serotonin function in humans. This is of relevance
as ATD Moja-De so far is the only ATD protocol that can
be administered to children and adolescents. Following
this, the present findings support the use of ATD Moja-De
in youngsters, allowing to probe the effects of a short-term
decrease in central nervous 5-HT synthesis in youths with
different neuropsychiatric disorders as well as healthy
subjects. Moreover, as can be seen from the plasma data
obtained both total and free TRP decreased significantly
under influence of ATD Moja-De, supporting the use of
total TRP concentrations in plasma as an estimate for the
decrease in central nervous TRP availability after ingestion
of ATD Moja-De. This is of relevance, in particular as the
determination of free TRP in plasma may cause significant
additional costs. The findings of the present study also need
to be seen in the light of some limitations. First, although
the use of Michaelis–Menten kinetics is a well-established
procedure (with evidence coming from multiple animal and
human studies), in order to perform calculations as done in
the present work this particular approach still provides a
somewhat indirect method to estimate a decrease in central
nervous 5-HT synthesis in humans. Further studies, for
example using positron emission tomography (PET) in
combination with ATD Moja-De would be of particular
relevance in order to provide reliable data with respect to
changes in receptor binding potentials related to seroto-
nergic neurotransmission under influence of ATD Moja-
De. Such data would also provide valuable information
with respect to brain areas affected by ATD Moja-De.
Second, data on potentially induced oxidative stress under
influence of ATD Moja-De, in particular after prolonged
depletion (for example several days), are lacking, and
which should be the subject of future research.
The validity of ATD has been recently questioned in a
review article, although the authors of this review did not
deny the fact that ATD lead to lowered central nervous
5-HT synthesis (van Donkelaar et al. 2011). One argument
raised was that ATD might also involve, or at least lead to,
nonserotonergic mechanisms, such as the effects of stress
(van Donkelaar et al. 2009b), metabolic and cerebrovas-
cular effects, and, in particular, a changed cerebral blood
flow (CBF). For example, studies on altered object memory
under ATD in rats showed an improvement after the
inhibition of phosphodiesterase (PDE), which in turn can
affect CBF, memory, and cognition-related processes
(Prickaerts et al. 2002a, b). In addition, ATD as indexed by
a diminished TRP/CAA ratio may inhibit nitric oxide
synthase (NOS), with evidence obtained from studies on
rats (Blokland et al. 1998; Prickaerts et al. 2002a). As a
consequence, subsequently diminished citrulline can lead
to a reduced nitric oxide (NO) synthesis (Dawson and
Dawson 1996; Lieben et al. 2004; van Donkelaar et al.
2009a). This can directly affect CBF.
A moderate rise in NO concentrations leads to dimin-
ished 5-HT release, in contrast to an increased 5-HT
release after a minor rise in NO levels (Kaehler et al. 1999;
van Donkelaar et al. 2011). In addition, the diminished
activity of different phosphodiesterase (PDE) isoenzymes
(PDE5-I, PDE2-I) facilitates NOS activity, affecting cog-
nition and memory through the outlined pathway (Kelly
et al. 1994, 1995; Blokland et al. 1998; Prickaerts et al.
2002a). PDE5-I and PDE2-I facilitate levels of second
messengers, such as cyclic guanosine monophosphate
Fig. 2 Plasma concentrations
(lmol/l) of the a total and b free
TRP at the time points T0–T3
after the intake of acute
tryptophan depletion (ATD) and
a balanced amino acid load
(BAL). The data are represented
as the mean values ± SD
V. L. S. Dingerkus et al.
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(cGMP) and cyclic adenosine monophosphate (cAMP),
with cGMP and cAMP having an impact on memory and
learning (van Donkelaar et al. 2011; Domek-Lopacinska
and Strosznajder 2008; Murad et al. 1978). However, to
date, evidence supporting these mechanisms in relation to
ATD in humans is lacking. Moreover, as stated by Crockett
et al. (2011), there is sufficient evidence indicating that
ATD clearly diminishes stimulated 5-HT release and,
above all, brain 5-HT. Further secondary mechanisms
related to ATD, in particular processes that can affect CBF,
need to be taken into consideration and should be the
subject of further investigation.
CBF is also known to impact the ratio of free TRP to
albumin-bound TRP. As outlined by van Donkelaar et al.
(2011), the interaction between the glycocalix of the
blood–brain barrier and albumin-bound TRP can be
increased by low CBF, resulting in a higher dissociation of
TRP from albumin (Pardridge and Fierer 1990; Smith et al.
1987b; van Donkelaar et al. 2011). There is a notable
debate over whether free or total TRP reflects the reduced
influx of TRP over the blood–brain barrier most accurately.
On the one hand, data obtained in rats suggest a positive
correlation between free TRP and TRP concentrations in
the whole brain (Oldendorf and Szabo 1976; Biggio et al.
1974). Moreover, the dissociation of albumin-bound TRP
induced by endogenous and exogenous ligands resulted in a
stronger influx of TRP into the CNS (van Donkelaar et al.
2011; Gessa and Tagliamonte 1974; Tagliamonte et al.
1973). On the other hand, there is also evidence supporting
the hypothesis that total TRP concentrations represent a
better indicator for the decreased influx of TRP into the
brain after ATD administration, which is partly in line with
the present results. In particular, TRP is known to be
loosely bound to albumin, and albumin was shown to
undergo significant conformational changes, although it
cannot enter the CNS alone (van Donkelaar et al. 2011;
Reed and Burrington 1989). In turn, as outlined by van
Donkelaar et al. (2009a, b, 2011), the reported conforma-
tional changes support a dissociation of TRP from albumin
in the cerebral microvasculature and depend on cerebral
haemodynamical processes (Pardridge and Fierer 1990).
Furthermore, an altered CBF can affect the interaction
between albumin-bound TRP and the blood–brain barrier
glycocalix with a diminished CBF leading to a higher
dissociation rate of TRP from albumin (van Donkelaar
et al. 2011; Pardridge and Fierer 1990; Smith et al. 1987b).
As shown by the present data, the ATD Moja-De para-
digm leads to a significant reduction in both the fTRP and
TRP concentrations, suggesting that this particular ATD
protocol leads to a robust reduction in the uptake of TRP
into the CNS and subsequently, to a lowered 5-HT syn-
thesis rate (see Figs. 1a, b, 2a, b). In conclusion, as outlined
by van Donkelaar et al. (2011), spatial as well as temporal
dynamic changes in CBF can impact TRP uptake into the
brain. This bears a close relationship to the previously
mentioned trials on altered object memory under ATD in
rats (Blokland et al. 1998; Prickaerts et al. 2002a), sug-
gesting that NOS, NO and PDE isoenzymes play a decisive
role in these parameters with respect to ATD-induced
effects, which are not solely dependent on a diminished
5-HT synthesis rate, in particular when memory and cog-
nition are concerned (Kelly et al. 1994, 1995).
The discovery that ATD Moja-De decreases TRP influx
across the blood–brain barrier could also be of clinical
value. For example, future research could aim to probe the
susceptibility to an acute central nervous system 5-HT
dysfunction as achieved by ATD and examine the physio-
logical, affective and behavioral responses under ATD as a
potential outcome predictor, e.g., as regards treatment with
SSRIs in patients with depression and other mood disorders,
as well as eating disorders. However, at this stage, ATD
Moja-De must be considered as a primarily experimental
paradigm to probe the effects of a short-term reduction in
central nervous 5-HT synthesis, and the value of ATD Moja-
De as a clinical neurodietary challenge test in vulnerable
populations needs to be confirmed by future investigations.
In summary, the present investigation indicates that
ATD Moja-De effectively diminishes TRP influx into the
brain and CNS 5-HT synthesis in healthy adults, as mea-
sured by a decreased substrate availability for central ner-
vous 5-HT synthesis. Future studies with larger samples of
both healthy humans and patients with neuropsychiatric
disorders related to changes in serotonergic neurotrans-
mission might illuminate the underlying relationship
between the central nervous availability of 5-HT and
changes in neurotransmission in neuropsychiatric disorders
and other phenotypes related to mental illness. The Moja-
De ATD paradigm allows such research to be undertaken
from a developmental viewpoint because it effectively
decreases TRP influx into the brain and can be adminis-
tered to children and adolescents.
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